Galderma, a global leader in the dermatological space, has officially announced that the U.S. Food and Drug Administration (FDA) has approved Restylane Contour for the correction of temporal fossa hollowing, commonly referred to as temple hollowing, in adults over the age of 21. This approval marks a significant expansion for the Restylane portfolio, specifically utilizing the proprietary XpresHAn Technology to address a traditionally difficult-to-treat area of the upper face. The decision by the regulatory body is supported by robust clinical data indicating that the injectable hyaluronic acid (HA) filler provides not only immediate volume restoration but also long-lasting aesthetic improvements that persist for over a year and a half.
The temple region is a critical component of facial harmony, yet it is often overlooked in traditional aesthetic consultations. As individuals age, the loss of subcutaneous fat, thinning of the skin, and bone resorption in the temporal area can lead to a "gaunt" or "skeletal" appearance. This hollowing can also create the illusion of a drooping brow or an exaggerated appearance of the bony ridges around the eyes. By securing FDA approval for this specific indication, Galderma provides aesthetic practitioners with a validated, safe, and effective tool to restore the natural contours of the upper face, contributing to a more balanced and rejuvenated profile.
Clinical Trial Data and Patient Outcomes
The FDA’s approval was predicated on the results of a comprehensive Phase 3 clinical study involving 225 participants across multiple research sites. The study was designed to evaluate the safety and effectiveness of Restylane Contour when injected into the temporal fossa using a specific, innovative technique. The data revealed that the product was highly effective in improving the appearance of temple hollowing, with results characterized by high levels of patient satisfaction and natural-looking movement.
One of the most compelling aspects of the clinical data is the longevity of the treatment. According to Galderma’s findings, 70% of study participants reported that they continued to feel they looked younger, less tired, and more refreshed 18 months after their initial treatment. Furthermore, 85% of participants maintained that their temples looked natural at the 18-month mark. This duration of effect is particularly noteworthy in the dermal filler market, where many HA products require more frequent maintenance intervals.
The safety profile observed during the clinical trials was consistent with previous studies of Restylane Contour. The most common side effects reported were injection-site reactions, such as bruising, swelling, redness, and tenderness, most of which were mild in severity and resolved within a few days. The study also highlighted the importance of the injection technique, which was tailored to the complex anatomy of the temporal region to minimize risks and maximize the aesthetic "lift" provided by the gel’s unique rheology.
The Science of XpresHAn Technology
Restylane Contour’s efficacy in the temple region is largely attributed to Galderma’s XpresHAn Technology, also known internationally as OBT (Optimal Balance Technology). Unlike traditional fillers that may act as static implants, XpresHAn Technology involves a specific cross-linking process that allows the hyaluronic acid gel to integrate seamlessly into the tissue. This creates a flexible support structure that moves with the patient’s natural facial expressions.
In the temples, where the skin is relatively thin and the underlying structure is firm, the filler must provide enough "G-prime" (firmness) to lift the hollowing while remaining supple enough to avoid a visible "lumpiness" or an unnatural look when the patient smiles or moves their face. The balance achieved by Restylane Contour allows for a smooth transition between the forehead and the cheekbones, effectively softening the transition and restoring the "heart-shaped" or "oval" face associated with youth.
Addressing the "Ozempic Face" Phenomenon
The timing of this FDA approval is particularly relevant given the shifting landscape of medical aesthetics. Bill Andriopoulos, Head of Global Medical Affairs at Galderma, noted that the rising popularity of medication-driven weight loss, such as GLP-1 receptor agonists (e.g., Ozempic, Wegovy, and Mounjaro), has created an increased demand for volume restoration.
Rapid and significant weight loss often results in a phenomenon colloquially termed "Ozempic Face," characterized by a loss of facial fat pads, skin laxity, and pronounced hollowing in the cheeks and temples. As more patients undergo medical weight loss treatments, the aesthetic industry is seeing a surge in individuals seeking non-surgical interventions to correct the gaunt appearance that can follow. Restylane Contour for temples is positioned as a primary solution for this demographic, allowing for the restoration of volume that looks authentic and aligns with the patient’s new physique.
A Chronology of Restylane Innovation
The approval for temple hollowing is the latest milestone in a long history of innovation for the Restylane brand. Galderma has consistently sought to refine the applications of hyaluronic acid since the original Restylane filler became the first HA filler to receive FDA approval in 2003.
- 1996: Restylane is launched in Europe, pioneering the use of non-animal stabilized hyaluronic acid (NASHA).
- 2003: The FDA approves Restylane for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.
- 2011: Restylane-L (with lidocaine) is approved, improving patient comfort during procedures.
- 2017: The FDA approves Restylane Refyne and Restylane Defyne, the first products in the U.S. to utilize XpresHAn Technology for flexible movement in the lower face.
- 2020: Restylane Kysse is approved for lip augmentation and the correction of upper perioral rhytids, specifically designed for the sensitive lip area.
- 2021: Restylane Contour receives its initial FDA approval for cheek augmentation and the correction of midface contour deficiencies.
- 2024: Restylane Contour receives FDA approval for the correction of temple hollowing, expanding its utility into the upper face.
This timeline illustrates Galderma’s strategy of "indication-specific" approvals, ensuring that each product in their portfolio is backed by rigorous clinical evidence for the specific anatomical area it is intended to treat.
Professional Perspectives and Market Impact
Aesthetic healthcare professionals have welcomed the approval, noting that the temples are a high-stakes area for injection due to the presence of the superficial temporal artery and other vital structures. Having an FDA-approved product with a validated injection protocol provides a level of safety and standardized training that benefits both the injector and the patient.
"The temple is often the ‘missing link’ in full-face rejuvenation," says industry analysis. "When we treat the cheeks and the jawline but ignore the temples, the result can look incomplete or top-heavy. This approval allows us to address the upper third of the face with confidence, knowing that the product has the right viscosity and longevity to withstand the pressures of the temporal fossa."
The global dermal filler market is projected to continue its upward trajectory, driven by increasing consumer awareness and the "prejuvenation" trend among younger demographics. By expanding the indications for Restylane Contour, Galderma is tapping into a market segment that values long-term results and "natural" aesthetics over the "overfilled" looks of previous decades.
Safety and Procedural Considerations
While the approval of Restylane Contour for temples is a major advancement, Galderma and the FDA emphasize that the procedure should only be performed by licensed healthcare professionals who have received specialized training in facial anatomy and injection techniques. The temporal region is anatomically complex, and improper injection could lead to serious complications, including vascular occlusion.
To support the rollout, Galderma is expected to launch comprehensive training programs through its Galderma Aesthetic Injector Network (GAIN). These programs focus on the "innovative injection technique" mentioned by Andriopoulos, which typically involves deep supraperiosteal injections or retrograde linear threading to ensure the filler is placed in the correct anatomical plane.
Patients considering the treatment are advised to consult with an experienced provider to determine if they are suitable candidates. Contraindications remain standard for HA fillers, including patients with severe allergies (especially to gram-positive bacterial proteins) or those with bleeding disorders.
Conclusion and Future Outlook
The FDA approval of Restylane Contour for temple hollowing represents a pivotal moment for Galderma and the broader aesthetic medicine community. By providing a scientifically backed solution for temporal wasting, Galderma is addressing a significant gap in the facial rejuvenation market. The 18-month longevity and high patient satisfaction rates set a high bar for competitors and offer patients a durable, cost-effective option for maintaining a youthful appearance.
As the industry continues to evolve—influenced by trends in weight loss, "quiet luxury" in aesthetics, and advancements in biotechnology—Galderma’s commitment to clinical excellence ensures that its portfolio remains at the forefront of dermatological care. With this new indication, Restylane Contour solidifies its status as a versatile tool capable of restoring not just volume, but the confidence and self-image of patients worldwide.